While race and ethnicity reporting in dermatology clinical trials has slightly improved in the last 5 years, 1,2 the proportion of studies with adequate racial and ethnic diversity remains unchanged. Despite National Institutes of Health (NIH) diversity mandates 3 and 2020 Food and Drug Administration (FDA) guidelines, 4 dermatology continues to underreport race and ethnicity demographic data in clinical trials.Why is diversity in clinical trials a critical aim for dermatology as a specialty? Reporting race and ethnicity in clinical trial publications signifies its value and importance. Ensuring diversity among clinical trial participants should no longer be optional, as it accomplishes several important aims: it increases generalizability of the trial results, ensures safety and clinical benefit for diverse populations, and imparts fairness and equity. 5 A diverse study population helps to ensure that all members of society, regardless of race, ethnicity, gender identity, age, sex, or socioeconomic status, have access to new therapies and to incur the benefits and risks of a trial intervention equally. This includes both the potential benefits of high-quality tertiary care, new advanced therapies, and access to subspecialty physicians, as well as the potential risks of adverse effects of novel agents or interventions. Lack of equitable participation in clinical trials is a manifestation of systemic racism. If the dermatologic research community prioritizes addressing the systemic racism that results in the lack of equitable participation in clinical trials, previously marginalized patients move one step closer toward improved health outcomes and justice.Why does a lack of diversity in dermatologic clinical trials exist? Dermatology's troubled relationship with racism in clinical research may serve as part of the underpinnings of the mistrust of institutionalized medicine by racial and ethnic minority communities. For example, the ethical abuses of the Tuskegee syphilis study are widely known-Black study participants were prevented from accessing syphilis treatment even as they were incurring permanent morbidity, including, but not limited to, dermatologic gummas, tissue destruction, and death from an otherwise treatable illness. But few may know of the experiments conducted at Holmesburg Prison in Philadelphia , led by dermatologist Albert Kligman, MD. 5,6 For 23 years, Kligman performed clinical trials using mostly incarcerated Black men to test the efficacy and safety of several dermatological treatments with funding from both pharmaceutical companies and government agencies. The most notable drug developed from these experiments is the widely used acne medication tretinoin. In the Holmesburg Prison experiments, research participants were subjected to significant harms of participation in clinical trials by way of exploitation, lack of informed consent, and coercion. These experiments highlight a disregard for margin-Opinion EDITORIAL jamadermatology.com (Reprinted)